Expression And Clinical Significance Of P-gp,TOPOII,GST-Ï€ And LRP In Colorectal Cancer

Objective To investigate the expression of P-gp, TOPOII, GST- π and LRP in colorectal cancer and evaluate its clinical significance, provide help to choose the drug of chemotherapy and predict the prognosis, obtain better therapy.Material and Methods P-gp, TOPOII, GST- π and LRP were measured in 80 cases of colorectal cancer tissues and 20 cases of benign disease by immunohistochemistry SP method using monoclonal antibody to their protein.Results The positive rate of P-gp, TOPOII, GST- π and LRP in colorectal cancer were 40%,55%,65% and 80% respectively. There was no difference of P-gp, TOPOII between colorectal cancer and benign disease. The expression of GST- π, LRP in colorectal cancer was significantly higher than that in benign disease. Their expression was not related to age, sex, position and pathology stage of the disease (P>0.05), but related to clinical stage, lymph node metastasis and tumor sides (P<0.05, 0.01). The expression of P-gp in clinic stage Ⅱ , Ⅲ was higher than stage Ⅰ. TOPOII in clinic stageⅢ were lower than stage Ⅰ , Ⅱ (P<0.05). The expression of GST- π in clinic stage III was higher than stage Ⅰ , Ⅱ (P<0.05). LRP in clinic stage Ⅱ , Ⅲ was higher than stage (P<0.05).Indicate they act independently in MDR of colorectal cancer.Conclusion A combined analysis of the expression of P-gp, TOPOII, GST- π and LRP in colorectal cancer may contribute to the election of drug in chemotherapy and prognosis evaluation of colorectal cancer. They act independently in MDR of colorectal cancer and are related to some clinicbiological behaviors.